

Chemosat®

www.chemosat.de



For more information on CHEMOSAT
or how to refer a patient, contact:

Ina Hellermann

German Regional Manager


+49 (0) 179 903 9339

ihellermann@delcath.com

PATIENT PATHWAY



Patient Timelines and Touchpoints*1



* Tests and timelines may vary depending on hospital and individual clinical needs. Subject to individual centre experience. The test and timeline protocol above has been adapted from the FOCUS study protocol.



Chemosat®

INDICATIONS FOR USE: The Delcath CHEMOSAT® Hepatic Delivery System is used for percutaneous intra-arterial administration of chemotherapeutic agent (melphalan hydrochloride) for perfusion of the liver with subsequent extracorporeal filtration of the regional (hepatic) venous blood, lowering the concentration of chemotherapeutic agent in the blood before returning it to the systemic venous circulation. Please refer to the Instructions for Use for full warnings and precautions. **NAME AND ADDRESS OF LEGAL MANUFACTURER:** Delcath Systems, Inc. 566 Queensbury Avenue, Queensbury, NY 12804, USA. **NAME AND ADDRESS OF EU AUTHORISED REP:** Delcath Systems Limited, Unit 19 Mervue Industrial Estate, Mervue, Galway, IRELAND, H91 EP89. **CE MARK AND NOTIFIED BODY NUMBER:** 2797. CHEMOSAT® is a registered trademark of Delcath Systems Inc. **WEBSITES:** www.delcath.com, www.chemosat.com, www.againsttheodds.com. EMEA-P-1026-v1 (v1.0) © 2024 Delcath Systems Ltd.

Reference: 1. Delcath Systems (2021), Data on File, REF-1344(v1.0)
FOCUS Informed Consent Form.